Applied DNA Sciences Files S-1/A Amendment

TL;DR

APDN filed an S-1/A, updating their registration. Looks like they're still cooking something up.

AI Summary

Applied DNA Sciences, Inc. filed an S-1/A amendment on May 21, 2024, for its registration statement. The company, previously known as ProHealth Medical Technologies Inc., DCC Acquisition Corp., and Datalink Capital Corp./TX/, is incorporated in Delaware and headquartered in Stony Brook, NY. James A. Hayward, Ph.D., Sc.D. is the Chairman, CEO, and President.

Why It Matters

This filing indicates ongoing regulatory activity and potential future stock offerings or changes for Applied DNA Sciences, Inc., which could impact investors and the market.

Risk Assessment

Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate changes, which can introduce volatility and risk for investors.

Key Numbers

• 333-278890 — SEC File Number (Identifies the specific registration statement being amended.)
• 20240521 — Filing Date (The date the amendment was officially submitted to the SEC.)

Key Players & Entities

• APPLIED DNA SCIENCES INC (company) — Registrant
• May 21, 2024 (date) — Filing Date
• 333-278890 (registration_number) — SEC File Number
• James A. Hayward, Ph.D., Sc.D. (person) — Chairman, Chief Executive Officer and President
• 50 Health Sciences Drive Stony Brook, New York 11790 (address) — Principal Executive Offices
• PROHEALTH MEDICAL TECHNOLOGIES INC (company) — Former Company Name
• DCC ACQUISITION CORP (company) — Former Company Name
• DATALINK CAPITAL CORP/TX/ (company) — Former Company Name

FAQ

Key Financial Figures

• $0.001 — sting of one share of our common stock, $0.001 par value per share, one Series A warra
• $2.51 — at the assumed public offering price of $2.51 per Unit, which was the last reported s
• $0 — luding one share of common stock, minus $0.0001, and the remaining exercise price
• $0.0001 — e of each Pre-Funded Warrant will equal $0.0001 per share. The Pre-Funded Warrants will
• $110,000 — t-of-pocket expenses in an amount up to $110,000. In addition, we have agreed to issue t

Filing Documents

• tm2412319d4_s1a.htm (S-1/A) — 519KB
• tm2412319d4_ex4-15.htm (EX-4.15) — 115KB
• tm2412319d4_ex4-16.htm (EX-4.16) — 137KB
• tm2412319d4_ex5-1.htm (EX-5.1) — 21KB
• tm2412319d4_ex23-1.htm (EX-23.1) — 2KB
• tm2412319d4_ex-filingfees.htm (EX-FILING FEES) — 49KB
• tm2412319d1_s1img01.jpg (GRAPHIC) — 20KB
• tm2412319d1_s1img02.jpg (GRAPHIC) — 29KB
• tm2412319d2_ex5-1img01.jpg (GRAPHIC) — 4KB
• tm2412319d2_ex5-1img02.jpg (GRAPHIC) — 4KB
• 0001104659-24-063761.txt ( ) — 925KB

Forward-Looking Statements

Forward-Looking Statements 2 Prospectus Summary 3 Summary of the Offering 11

Use of Proceeds

Use of Proceeds 16 Market Price of our Common Stock and Related Stockholder Matters 16 Capitalization 17

Description of Securities

Description of Securities 19 PLAN OF DISTRIBUTION 23 Experts 25 Legal Matters 25 Where you can find more information 26 MATERIAL CHANGES 26 Incorporation by Reference 26 ABOUT THIS PROSPECTUS The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any related free writing prospectus is delivered or securities are sold on a later date. We have not done anything that would permit this offering or possession or distribution of this pr

Forward-looking statements

Forward-looking statements may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, demand for our products and services, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Any of the assumptions underlying the forward-looking statements contained in this prospectus could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking-statements contained herein. PROSPECTUS SUMMARY This summary highlights certain information about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by reference in this prospectus. This summary is not complete and does not contain all of the information that you should consider before investing in our securities. After you carefully read this summary, to fully understand our Company and this offering and its consequences to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the information referred to under the heading "Risk Factors" in this prospectus beginning on page 12, and any related free writing prospectus, as well as the o

View Full Filing

View this S-1/A filing on SEC EDGAR